Bezuclastinib(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

Sponsor:

Cogent Biosciences, Inc.

Code:

NCT04996875

Conditions

Advanced Systemic Mastocytosis (AdvSM)

SM With an Associated Hematologic Neoplasm (SM-AHN)

Mast Cell Leukemia (MCL)

Aggressive Systemic Mastocytosis (ASM)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

bezuclastinib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-25. This information was provided to ClinicalTrials.gov by Cogent Biosciences, Inc. on 2026-07-31.